Psoas Hematoma Following Lumbar Sympathetic Block in a Patient with Renal and Liver Diseases and Recent Use of Aggrenox

Nashaat Rizk, Zirong Zhao, Munish Loomba

Department of Anesthesiology, UPMC Pain Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

DOI: 10.4236/ojanes.2014.44015                

Abstract

Lumbar sympathetic block is an analgesic procedure frequently performed in chronic pain clinics for ischemic lower limb pain from peripheral arterial disease. Although the lumbar sympathetic ganglia are anatomically near major vascular and neural structures, complications such as severe hemorrhage is rarely reported. Aspirin/extended release dipyridamole (Aggrenox) is indicated for secondary stroke prevention. Stroke is frequently a co-morbid condition in patients with peripheral vascular disease. Interventional pain physicians frequently face the difficulty of deciding whether to continue or stop antithrombotic medications in the periprocedural period because of the devastating consequences of both hemorrhagic and thrombotic complications. Due to a paucity of data, no guidelines have been specifically written for interventional procedures for chronic pain. To aid future decision making, we present a case report of psoas hematoma developed after lumbar sympathetic block in a patient with end stage renal failure and hepatic dysfunction who had limb-threatening ischemia. The patient was treated with Aggrenox until three days before the procedure.

Keywords

Psoas Hematoma, Lumbar Sympathetic Block, Antiplatelet, Aspirin, Dipyridamole

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Furie, K.L., Kasner, S.E., Adams, R.J., Alberts, G.W., Bush, R.L., Fagan, S.C., Halperin, J.L., Johnston, S.C., Katzan, I., Kernan, W.N., Mitchell, P.H., Ovbiagele, B., Palesch, Y.Y., Sacco, R.L., Schwamm, L.H., Wassertheil-Smoller, S., Turan, T.N. and Wentworth, D. (2011) Executive Summary: Guidelines for the Prevention of Stroke in Patients with Stroke or Transient Ischemic Attack. Stroke, 42, 227-276. http://dx.doi.org/10.1161/STR.0b013e3181f7d043
[2]	Feigin, V.L., Lawes, C.M.M., Bennett, D.A. and Anderson, C.S. (2003) Stroke Epidemiology: A Review of Population-Based Studies of Incidence, Prevalence, and Case-Fatality in the Late 20th Century. The Lancet Neurology, 2, 43-53. http://dx.doi.org/10.1016/S1474-4422(03)00266-7
[3]	Horlocker, T.T., Wedel, D.J., Rowlingson, J.C., Enneking, F.K., Kopp, S.L., Benzon, H.T., Brown, D.L., Heit, J.A., Mulroy, M.F., Rosenquist, R.W., Tryba, M. and Yuan, C. (2010) Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy, American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guideline (3rd Edition). Regional Anesthesia and Pain Medicine, 35, 64-101.
[4]	Kauppila, L.I. (1994) Blood Supply of the Lower Thoracic and Lumbosacral Regions, Postmortem Aortography in 38 Young Adults. Acta Radiologica, 35, 541-544.
[5]	Pillet, J., Chevalier, J.M., Rasomanana, D., Enon, B., Mercier, P., Lescalie, F., Moreau, F. and Cronier, P. (1989) The Principle Artery of the Psoas Major Muscle. Surgical-Radiologic Anatomy, 11, 33-36. http://dx.doi.org/10.1007/BF02102243
[6]	Maier, C., Gleim, M., Weiss, T., Stachetzki, U., Nicolas, V. and Zenz, M. (2002) Severe Bleeding Following Lumbar Sympathetic Blockade in Two Patients under Medication with Irreversible Platelet Aggregation Inhibitors. Anesthesiology, 97, 740-743. http://dx.doi.org/10.1097/00000542-200209000-00032
[7]	Manchikanti, L., Falco, F.J.E., Benyamin, R.M., Caraway, D.L., Kaye, A.D., Helm II, S., Wargo, B.W., Hansen, H., Parr, A.T., Singh, V., Swicegood, J.R., Smith, H.S., Schultz, D.M., Malla, Y. and Hirsch, J.A. (2013) Assessment of Bleeding Risk of Interventional Techniques: A Best Evidence Synthesis of Practice Patterns and Perioperative Management of Anticoagulant and Antithrombotic Therapy. Pain Physician, 16, SE261-SE318.
[8]	Burch, J.W., Stanford, N. and Majerus, P.W. (1978) Inhibition of Platelet Prostaglandin Synthetase by Oral Aspirin. The Journal of Clinical Investigation, 61, 314-319. http://dx.doi.org/10.1172/JCI108941
[9]	Lenz, T.L. and Wilson, A.F. (2003) Clinical Pharmacokinetics of Antiplatelet Agents Used in the Secondary Prevention of Stroke. Clinical Pharmacokinetics, 42, 909-920. http://dx.doi.org/10.2165/00003088-200342100-00003
[10]	Hervey, P.S. and Goa, K.L. (1999) Extended-Release Dipyridamole/Aspirin. Drugs, 58, 469-476. http://dx.doi.org/10.2165/00003495-199958030-00007
[11]	Kaw, D. and Malhotra, D. (2006) Platelet Dysfunction and End-Stage Renal Disease. Seminars in Dialysis, 19, 317-322. http://dx.doi.org/10.1111/j.1525-139X.2006.00179.x
[12]	Raj, P.P., Shah, R.V., Kaye, A.D., Denaro, S. and Hoover, J.M. (2004) Bleeding Risk in Interventional Pain Practice: Assessment, Management, and Review of the Literature. Pain Physician, 7, 3-51.